header logo image


Page 17«..10..16171819..»

Archive for the ‘Stem Cell Russia’ Category

Stem cell therapy in Moscow, Russia – medica-tour.com

Sunday, November 4th, 2018

The clinic has been engaged in the development, testing, production and introduction of new medicinal, cosmetic and prophylactic products based on biomedical cell products for more than 9 years.

A new medical technology for the production of high-quality mesenchymal stem cells from the human bone marrow, obtained with puncture of the sternum or iliac bone from donors, has been developed. It is based on the multiplication in culture under strictly defined conditions of a net population of mesenchymal stem cells to 100-500 million from a small initial amount of bone marrow (0.5-1.0 ml). This amount is sufficient for effective cell therapy.

The clinic has permission to use the new medical technology of the Federal Service for Supervision in Health and Social Development No. FS No. 2010/359 "Fence, cultivation of EX VIVO multipotent mesenchymal stromal cells of the human bone marrow and their storage" from 21.09.2010.

The clinic in Moscow also has its own stem cell bank of human bone marrow. The production of cellular products is carried out on modern equipment by highly qualified specialists in accordance with the enterprise standard. A large research work was carried out to create a composition consisting of mesenchymal stem cells and a product of their vital activity, a conditioned medium.

The Moscow clinic offers a real alternative to standard treatment, cooperates with the best specialists of various medical fields, who have many years of experience and a rich history of victories over various diseases. New medical technologies and products have been developed that have no analogues in their effectiveness.

Prices for stem cell therapy in Moscow are 3-3.5 times cheaper than similar treatment in other countries.

- Practically painless procedure for taking material

- Storage in a modern stem cell bank

- Extensive spectrum of application of own cells

- Short time of growing the cellular material

- The possibility of using stem cells by all family members

- Unique lines of cosmetics based on your cells

- Flexible pricing policy and individual approach

- Modern technology used in the world practice

- Diseases of the cardiovascular system (myocardial infarction, chronic heart failure, cardiomyopathy, etc.)

- Diseases of the nervous system (trauma of the brain and spinal cord, strokes, multiple sclerosis, etc.)

- Postural damage of various organs and tissues

- Diabetes mellitus, diabetic foot

- Liver disorders (hepatitis, cirrhosis)

- Destructive forms of pulmonary tuberculosis, resistant to antituberculous therapy

- Autoimmune diseases

- Trophic skin lesions, developed against a background of venous insufficiency, obliterating endarteritis; decubitus

- Burns (thermal, chemical, radiation)

- Aesthetic dermatology

- General health improvement (revitalization)

- No side effects

- Material created by nature itself

- Minimal contraindications for use

- Simple and painless procedure of administration

- In some cases, the result is visible after a single injection

- Absence of problems in the availability of cellular material, since it can be reproduced practically indefinitely

Mesenchymal stem cells are used if:

- Standard treatment does not help

- It is necessary to quickly restore body functions

- To improve the quality of life and its duration

- To find beauty and youth

- Prevent occurrence or stop the development of diseases

Today the level of medical technology is at an unprecedented height, and the whole world is smoothly moving from mass treatment to personalized ones. The Moscow clinic has a staff of highly qualified specialists with vast experience and its own laboratory equipped with all international standards. Based on many years of experience, a unique product has been created that will enable you and your loved ones to maintain health and youth for years to come.

It is about "personal biological insurance". Its concept is that you or your relatives can hand over a piece of their own biological material for storage and later use it for treatment, prevention or rejuvenation. Your material is banked and placed in the cryobank. You can use it at any time to carry out cellular therapy for the disease or its prevention, as well as to maintain overall body health and prolong youth and longevity.

Scientific works say that our bodies have a certain number of mesenchymal stem cells, which after 30 years begin to decline. This leads to a decrease in immunity and protective properties of the body and, accordingly, to loss of efficiency, aging and makes the body unable to combat various diseases. The uniqueness of the clinic's product is that once your cells are handed over once, your entire family can use them almost unlimited times.

You can also get a unique opportunity to use your own cells in various products, be it skin care cream, gel for wound healing and burns, as well as shampoos, masks, sprays, etc. All this is due to the technology of the main one in creating a conditioned environment containing metabolic products of mesenchymal stem cells. You can maintain skin health at home using the resource of your own organism, namely your own stem cells.

Send an application:

'); $('.preloader', contact_form).fadeIn('fast').delay(800).fadeOut('fast'); return true }; // Prepare form var options = { target: '#ajax_form_box_box_1', beforeSubmit: formValidate, type: 'post' }; $('#ajax_form_box_box_1 form input[name*=returnid]').attr('value','383');$('#ajax_form_box_box_1 form input[name=page]').attr('value','stem-cell-therapy-in-moscow-russia'); contact_form.attr('action','https://medica-tour.com:443/forclients/stem-cell-therapy-in-moscow-russia?showtemplate=false&formid=1').ajaxForm(options); });

More here:
Stem cell therapy in Moscow, Russia - medica-tour.com

Read More...

CTERP International Conference – 2018: About

Tuesday, September 25th, 2018

CTERP INTERNATIONAL CONFERENCEApril 11-13, 2018Moscow, Russia

In recent years there have been rapid advances in applying the discoveries in cell technologies field into medical practice. Cell technologies are progressing as the result of multidisciplinary effort of scientists, clinicians and businessmen,with clinical applications of manipulated stem cells combining developments in transplantation and gene therapy.Challenges address not only thetechnology itself but also compliancewith safety and regulatory requirements.

The Conference will provide a platform for scientists from basic and applied cell biology fields, practical doctors, and biotech companies to meet and share their experience, to discuss the research associated with developing biomedical clinical products and translating this research into novel clinical applications, challenges of such translational efforts and foundation of bioclusters assisting further developments in cell technology.

The official language of the conference is English.

Conference materials will be published in the Russian Journal of Developmental Biology.

Please download your abstracts in accordance with the journal guidelines (english, russian) for authors provided on their website.

Continued here:
CTERP International Conference - 2018: About

Read More...

Information in English – msclerosis.ru

Thursday, August 16th, 2018

The A.A. Maximov Hematology and Cell Therapy Department of the National Pirogov Medical Surgical Centre specializes in the state-of-the-art treatment of hematological, oncological and autoimmune diseases. The accommodation standards and quality of medical care in the Department are at least equal to those of leading American and Western European medical centers.

Of special interest for our foreign guests is an innovative technology of high-dose immunosuppressive therapy with hematopoietic stem cell transplantation in autoimmune diseases.

Autoimmune diseases are a heterogeneous group of disorders caused by an attack of a patient's own healthy tissues by his/her immune system. This group includes multiple sclerosis, rheumatoid arthritis, Crohn's disease, systemic lupus erythematosus and many other diseases.

Multiple sclerosis is one of widespread autoimmune diseases of the nervous system. It is a chronic inflammatory disorder of the central nervous system, caused by autoimmune reactivity of T-cells towards components of neural cells. Although multiple sclerosis is a non-life-threatening disorder, its progression inevitably leads to impairment of the patient's ability to move, sensitive disturbances and cognitive impairment. The disease progresses slowly and, at the end, the patient is essentially confined to a wheelchair.Conventional therapies do not provide satisfactory control of multiple sclerosis. Hormonal therapy helps to limit acute manifestations of the disease, but it cannot stop its progression. Interferon therapy may help some patients, but in most cases it does not provide a stable long-term effect.

NEW PROMISING THERAPY FOR MULTIPLE SCLEROSIS PATIENTS IS HIGH-DOSE IMMUNOSUPRESSIVE THERAPY WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION.

Chemotherapy eliminates the cause of the disease - autoimmune T-cells that are responsible for the nervous tissue damage. Then the patient is transplanted with his/her own (autologous) stem cells, which were collected and frozen in advance. This approach may stop the progression of the disease in most patients and prevent further decrease of their quality of life. Importantly, multiple sclerosis patients do not need any maintenance therapy after transplantation.

Hematopoietic stem cell transplantation in multiple sclerosis has been studied in the USA and Europe since 1995. During last decade more than 700 patients have received this treatment. According to the European Registry, the efficiency of high-dose immunosuppressive therapy with hematopoietic stem cell transplantation in multiple sclerosis approximates 75%-80%. It is most effective in young patients with rapidly progressing multiple sclerosis in its early stages, when the leading mechanism of the damage to the nervous system is autoimmune inflammation. Later in the course of the disease, when the irreversible damage is done, the effect of the transplantation is limited.

High-dose immunosuppressive therapy with hematopoietic stem cell transplantation holds great promise as an effective tool for treatment of other autoimmune diseases, namely rheumatoid arthritis, Crohn's disease, pemphigus vulgaris and systemic lupus erythematosus.

The specialists of our Department have accumulated vast experience in applying stem cell transplantation to the treatment of autoimmune diseases. Our results were reported at major international meetings and received an unambiguous support from experts in the field. Importantly, this approach has nothing to do with the so called "cell therapy" approaches that are popular in Russia nowadays. Stem cells which are transplanted to a patient are his own (autologous) stem cells and are by no means of fetal origin. Chemotherapy and stem cell transplantations are performed according to the standards of the European Bone Marrow Transplantation (EBMT) Organization and International Society of Cellular Therapy (ISCT). We carefully weigh risk and benefits of transplantation in every individual case. Detailed examination always precedes the final decision about the appropriateness of high-dose immunosuppressive therapy with hematopoietic stem cell transplantation.

We will be happy to provide you with further information on the possibility of treatment in our Department.Phone/Fax +7 495 603-72-17Phone +7 915 290-00-67e-mail: info@gemclinic.ru

Go here to see the original:
Information in English - msclerosis.ru

Read More...

Human Stem Cells Institute

Friday, July 6th, 2018

Human Stem Cells Institute PJSC (HSCI) is a Russian public biotech company founded in 2003.

HSCI is engaged in drug discovery, R&D and marketing of innovative proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics,gene therapy and biopharmaceutics.

The Company aims to foster a new culture of medical care developing new health care opportunities in such areas as personalized and preventive medicine.

HSCI owns the largest family cord blood stem cell bank in Russia and the CIS Gemabank, as well as the reproductive cell and tissue bank Reprobank(personal storage and donation).

The Company launched Neovasculgen, the first-in-class gene therapy drug for the treatment of Peripheral Arterial Disease, including Critical Limb Ischemia, and also introduced the innovative cell technology SPRS-therapy, which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.

HSCI is implementing a socially significant Genetico project for the development of its own Medical genetics center & lab to provide a wide range ofgenetic testing and counseling serviceswith the aim of early identification, prediction and prophylactic treatment of genetic disorders, including reproductive system diseases(e.g. PGS/PGD,NIPT, Oncogenetics, Bioinformatics, diagnostic panels for specific disease categories and cases).

The Company actively promotes its products on the Russian market and intends to open new markets throughout the world.

HSCI is listed on the Innovation & Investment Market (iIM) of the Moscow Exchange (ticker ISKJ). The Company conducted its IPO in December 2009, becoming the first Russian biotech company to go public.

Read this article:
Human Stem Cells Institute

Read More...

Journal of Fertilization: In Vitro – IVF-Worldwide …

Monday, June 25th, 2018

IVF Treatment

Unlike artificial insemination wherein the sperm is introduced into uterus, in IVF, the sperm and egg are fertilized outside the uterus in laboratory conditions. The fertilized egg is then introduced into womans uterus. Most often, IVF is not the first treatment suggested for infertility because of its complex nature and costs involved in it.

Related Journals of IVF Treatment

Gynecology & Obstetrics; Andrology & Gynecology: Current Research; Andrology-Open Access; Reproductive Biomedicine Online; Human Reproduction; Fertility and Sterility; Molecular Human Reproduction, Journal of Assisted Reproduction and Genetics; Acta Obstetricia Et Gynecologica Scandinavica; European Journal of Obstetrics & Gynecology and Reproductive Biology

Recent advances and latest techniques in IVF treatment are enabling to achieve high success rates and minimizing the chances of multiple pregnancies and birth defects. The refinements are being done in every step of IVF i.e., ovarian stimulation, collection of sperm, fertilization, embryo development in lab conditions and introduction of embryo into uterus.

Related Journals of Advances in In-vitro Fertilization

International Journal of Andrology, Gynecology & Obstetrics; Andrology-Open Acce; Andrology & Gynecology: Current Research; Journal of Assisted Reproduction and Genetics; Fertility and Sterility; American Journal of Obstetrics and Gynecology; Reproductive Biology and Endocrinology; Archives of Gynecology and Obstetrics; Reproductive Medicine and Biology

Infertility is when not being able to achieve pregnancy even after regular intercourse. It is the most common problem which suffers the couples from having children. Many treatments have been available with different success rates. They include fertility drugs, intrauterine insemination (IUI), in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), donor insemination (DI), egg (or embryo) donation and surrogacy.

Related Journals of Infertility Treatment

Gynecology & Obstetrics; Critical Care Obstetrics & Gynecology; Andrology & Gynecology: Current Research; Infertility and Reproductive Medicine Clinics of North America; Journal of Reproduction and Infertility; International Journal of Infertility and Fetal Medicine; Iranian Journal of Obstetrics, Gynecology and Infertility;Reproductive Biomedicine Online; Human Reproduction

Artificial Insemination (AI) is one of the infertility treatments available for both men and women. In this technique, the sperm is directly introduced into womans uterus, fallopian tube or cervix. The most common form of artificial insemination is intra Uterine Insemination (IUI). Although the success rate of this technique is less, it is the first infertility treatment doctor would suggest as it involves less cost and the treatment method is simple.

Related Journals of Artificial Insemination

Critical Care Obstetrics & Gynecology; Gynecology & Obstetrics; Andrology & Gynecology: Current Research; Theriogenology;Journal of Dairy Science; Animal Reproduction Science; Reproduction; Reproduction Fertility and Development; Reproduction in Domestic Animals

Reproductive genetics is a sub-filed of medical genetics that primarily involve conducting different tests for predicting possible outcomes of future pregnancies. The tests involve analyzing genetic material like chromosomes, genes, DNA, RNA and gene products for accessing genetic changes that have likelihood of causing some disease after pregnancy in either mother or child.

Related Journals of Reproductive Genetics

Human Reproduction and Genetic Ethics, Reproductive System & Sexual Disorders; Current Trends in Gynecologic Oncology; Andrology & Gynecology: Current Research; Journal of Assisted Reproduction and Genetics; Conservation Genetics; Animal Reproduction Science; Reproductive Biomedicine Online; Human Reproduction Update; PLoS Genetics

Semen analysis is the most common way of accessing infertility in men. It basically evaluates the quality and environment of sperm. The analysis involves testing various sperm parameters such as sperm morphology, sperm count, sperm motility etc. It helps to test sperm donors for quality sperm to be used in assisted reproductive techniques.

Related Journals of Semen Analysis and Sperm Characteristics

Andrology & Gynecology: Current Research; Andrology-Open Access; Reproductive System & Sexual Disorders; Fertility and Sterility; Asian Journal of Andrology; Theriogenology; Human Reproduction; Journal of Assisted Reproduction and Genetics; Reproductive Biomedicine Online

Endometriosis is disease condition in woman in which the tissue which normally grows inside the uterus will grow outside the uterus. The side effects of the condition are pelvic pain and infertility. In 70% of the cases, the pelvic pain would be severe during menstruation. The cause for such condition is not clearly understood yet.

Related Journals of Endometriosis Treatment

Gynecology & Obstetrics; Critical Care Obstetrics & Gynecology; Andrology & Gynecology: Current Research; Journal of Endometriosis; Journal of Minimally Invasive Gynecology; Human Reproduction; Fertility and Sterility; International Journal of Gynecology & Obstetrics; Obstetrical & Gynecological Survey

See the rest here:
Journal of Fertilization: In Vitro - IVF-Worldwide ...

Read More...

U.S. Department of Justice Files Lawsuit at Request of FDA …

Wednesday, June 20th, 2018

U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead, developmental product Adipocell, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company's business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Media Contact: U.S. Stem Cell, Inc. 13794 NW 4th Street, Suite 212Sunrise, Fl 33325Phone: 954.835.1500Email: usstemcell@us-stemcell.com

View original content with multimedia:http://www.prnewswire.com/news-releases/us-department-of-justice-files-lawsuit-at-request-of-fda-to-stop-us-stem-cell-clinic-from-performing-autologous-stem-cell-procedure-300645973.html

SOURCE U.S. Stem Cell, Inc.

Home

See the original post here:
U.S. Department of Justice Files Lawsuit at Request of FDA ...

Read More...

How Stem Cell Therapy Can Help Repair and Regenerate Your Body

Wednesday, October 11th, 2017

By Dr. Mercola

Kristin Comella,1 named No. 1 on the Academy of Regenerative Practices list of Top 10 stem cell innovators, has been a stem cell researcher for nearly two decades. In this interview, she discusses the enormous regenerative potential of stem cell therapy.

Comella, who holds degrees in chemical and biomedical engineering, began working with stem cells in graduate school, using a technique called magnetic cell sorting, which involves tagging nanoparticle magnets onto cells and then separating the cells based on the proteins they express.

"What we've learned over the years is that stem cells express different proteins than other kinds of cells in your body," she explains. "That began my career in the field of stem cells."

Over the years, she's worked for several different companies. At a start-up in Maryland, she used stem cells from bone marrow (culture-expanded mesenchymal stem cells) for meniscus regeneration. By placing these cells directly into the knee joint, you can repair or even grow back a damaged meniscus.

For a time, she also headed up the Good Manufacturing Practices (GMP) facility at Tulane University, which is a U.S. Food and Drug Administration (FDA) facility located at the Tulane Center for Gene Therapy. There, her work revolved around using bone marrow mesenchymal stem cells for spinal cord regeneration.

For the past 13 years, she's worked for U.S. Stem Cell, a company founded in 1999. The company began bringing stem cells for cardiac care to the public. Muscle-derived stem cells can be used to repair heart damage associated with heart attacks. "Our company treated our first patient in 2001. Since that time, we've treated over 7,000 patients. We began looking at other indications about a decade ago. We also began looking at stem cells from a variety of different sources," she says.

The primary purpose of stem cells is to maintain, heal and regenerate tissues wherever they reside in your body. This is a continuous process that occurs inside your body throughout your life. If you didn't have stem cells, your lifespan would be about an hour, because there would be nothing to replace exhausted cells or damaged tissue. In addition, any time your body is exposed to any sort of toxin, the inflammatory process causes stem cells to swarm the area to repair the damage.

"As an example, you might have gone to the gym this morning [and] done some squats. As a result of that, you would get tiny tears inside the muscle. The stem cells that reside beneath the muscle would come out and repair all those tears.

The reason that, if you continuously go to the gym, you would start to build new muscle, is because those stem cells, hard at work underneath your muscle, are helping to repair and build that new muscle. This would apply to all of the tissues inside your body," Comella explains.

While it's easy to think of stem cell therapy as a magic bullet, it would be wise to implement strategies that nourish and thereby help optimize the stem cells you already have in your body. As noted by Comella:

"You have to create an appropriate environment for these cells to function in. If you are putting garbage into your body and you're constantly burdening your body with toxins, your stem cells are getting too distracted trying to fight off those toxins. By creating an appropriate environment, optimizing your diet and reducing exposure to toxins, that will allow the stem cells that we're putting in to really home in and focus on the true issue that we're trying to treat.

The other thing we've discovered over the years is that [stem cell therapy] is not the type of thing where you take one dose and you're cured forever. Your tissues are constantly getting damaged You're going to have to repeat-dose and use those stem cells to your advantage.

When you think about a lizard that loses its tail, it takes two years to grow back the tail. Why would we put unrealistic expectations on the stem cells that we're trying to apply to repair or replace damaged tissue? This is a very slow process. This is something that will occur over months and may require repeat dosing."

Historically, stem cells were isolated from bone marrow, and have been used for bone marrow transplants for cancer patients since the 1930s. However, you can get stem cells from just about any tissue in your body, as every tissue contains stem cells.

Your bone marrow actually has very low amounts of mesenchymal stem cells, which are now believed to be the most important, from a therapeutic perspective. Mesenchymal stem cells help trigger an immunomodulatory response or a paracrine effect, which means they send signals out to the rest of your body, calling cells to the area to help promote healing.

"What we've discovered in more recent years is that a more plentiful source of stem cells is actually your fat tissue. [Body] fat can contain up to 500 times more cells than your bone marrow, as far as these mesenchymal type stem cells go.

One thing that's also critically important when you're talking about isolating the cells is the number of other cells that are going to be part of that population. When you're isolating a bone marrow sample, this actually is very high in white blood cells, which are pro-inflammatory."

White blood cells are part of your immune response. When an injury occurs, or a foreign body enters your system, white blood cells will attack. Unfortunately, white blood cells do not discriminate, and can create quite a bit of damage as they clean the area out.

Stem cells, in particular your mesenchymal cells, quiet down the white blood cells and then start the regeneration phase, which leads to new tissue. Bone marrow tends to be very high in white blood cells and low in the mesenchymal cells. Isolating stem cells from fat tissue is preferred not only because it's easier on the patient, but fat also contains a higher population of mesenchymal cells and fewer white blood cells.

"The benefit also of isolating [stem cells from] fat is that it's a relatively simple procedure. There's typically no shortage of fat tissue, especially in Americans," Comella says. "[Also], as you age, your bone marrow declines with regards to the number of cells in it, whereas the fat tissue maintains a pretty high number of stem cells, even in older individuals.

We can successfully harvest fat off of just about anyone, regardless of their age or how thin they are. The procedure is done under local [anesthesia], meaning that the patient stays awake. They don't have to go under general anesthesia. We can harvest as few as 15 cubic centimeters of fat, which is a very small amount of fat, and still get a very high number of stem cells."

A stem cell procedure can cost anywhere from $5,000 to $15,000, depending on what you're having done, and rarely if ever will insurance cover it. Still, when you compare it to the cost of long-term medications or the out-of-pocket cost of getting a knee replacement, stem cell therapy may still be a less expensive alternative. Also, a single extraction will typically yield enough stem cells for 20 to 25 future treatments, should you decide to store your stem cells for future need.

"I think it's accessible for patients," Comella says. "It's an out-patient procedure. You plan to be in clinic for about two hours; no real limitations afterwards, just no submerging in water, no alcohol, no smoking for a week. But other than that, patients can resume their normal activities and go about their regular daily lives."

Interestingly, Comella notes that patients who eat a very healthy diet, focusing on organic and grass fed foods, have body fat that is very hearty and almost sticky, yielding high amounts of very healthy stem cells.

"We can grow much better and faster stem cells from that fat than [the fat from] somebody who eats a grain-based diet or is exposed to a lot of toxins in their diet," she says. "Their fat tends to be very fluffy, buttery yellow. The cells that come out of that are not necessarily as good a quality. It's just been very interesting. And of note, patients that are cigarette smokers, their fat is actually gray-tinged in color. The stem cells do not grow well at all."

What's been described above is what's called an autologous donation, meaning you're getting the stem cells from yourself. A number of companies provide non-autologous donations using cells harvested from other people, typically women, like amniotic or embryonic mesenchymal cells. This is an important distinction.

"There are now just a couple of studies that have been published comparing an autologous source, meaning cells from you own body, to an allogeneic source, meaning cells from someone else.

So far, what has been discovered is that the autologous cells, meaning your own cells, will outperform somebody else's cells inside your body. Now, this is not fully understood at this point. It may be that the environment that your cells function in, they're used to that environment. They recognize it. It's the same DNA and they can function well.

However, once you culture expand and get a pure population of these mesenchymal cells not necessarily the sample that's coming right off of the liposuction, but a sample that has been taken to the lab and grown those cells will not elicit an immune response if you use them in someone else. You could scientifically and medically use those in an unmatched person. However, there are some regulatory aspects of that with regards to the FDA."

In the U.S., there are a variety of new stem cell products available, referred to as amniotic, cord blood products or placenta products, which are prepared at a tissue bank. Such facilities must be registered with the FDA, and the products must undergo additional processing.

For example, they must be morselized, or snap frozen or blended in some way. Such processing typically breaks the membrane, releasing growth factors, and the resulting products are called acellular, meaning there are no living cells remaining in the sample.

The amniotic products available in the U.S. are not so much stem cell products as they are growth factor products. According to Comella, they can be useful in creating an immunomodulatory response, which can help to promote healing, but that still differs from the living stem cell procedures that can be done by either isolating cells from your fat or bone marrow. As a general rule, you don't achieve the clinical benefits when using an amniotic product, primarily because they don't contain living stem cells.

"I want to contrast that to what are called embryonic stem cells," Comella adds. "The products obtained from cord blood, from women who are having babies, are not embryonic stem cells. Embryonic stem cells are when you are first bringing the egg and sperm together. Three days after that, you can isolate what is called an inner cell mass. This inner cell mass can be used to then grow cells in culture, or that inner cell mass could eventually lead to the formation of a baby.

Those are embryonic stem cells, and those are pluripotential, meaning that they have the ability to form an entire being, versus adult stem cells or stem cells that are present in amniotic tissue, [which] are multipotential, which only have the ability to form subsets of tissue.

When you're dealing with different diseases or damaged tissue or inflammation, mostly you want to repair tissue. If somebody has damage in their knee, they don't necessarily need embryonic cells because they don't need a baby in their knee. They need new cartilage in their knee."

A common question is whether stem cells can cause overgrowth, leading to cancer or tumor formation. As noted by Comella, this is a problem associated with embryonic stem cells, which tend to grow very rapidly and can form a teratoma because of the rapid cell growth. Adult stem cells the cells obtained from your own body have growth inhibitions and will not form teratomas.

"The theoretical concern that has been addressed in animal models or in petri dishes is that if you take cancer cells that are growing in a dish and apply stem cells, it may make those cancer cells grow more rapidly. But this does not translate in-vivo to humans.

If there was truly an issue with applying stem cells to a patient who has cancer, we would know about it by now, because we've been dosing cancer patients with stem cells since the '30s. The safety profile is strong and there are tens of thousands of patients documented with these treatments," Comella says.

Another useful therapy is platelet-rich plasma (PRP). Your peripheral blood contains platelets, which act as first responders when there's an injury. They come in and start the clotting mechanism, thereby preventing you from bleeding to death. They also give marching orders to other cells. For example, platelets can command stem cells to multiply and grow, or to differentiate and form new tissue.

These platelets also have many different growth factors associated with them, which can help to promote healing and stop inflammation. PRP involves taking a blood sample and then spinning the blood in a centrifuge to isolate the platelets. The platelet-rich plasma is then injected back into the area that is inflamed.

"One of the most common uses of platelet-rich plasma or PRP is in a joint. Now, platelets are going to be most successful in something that is rich in stem cells [such as] an acute or a very recent injury.

If you just hurt your knee, the first thing you should do is get PRP, because it's going to help promote healing, and those platelets will attach to the surface receptors of the stem cells that are already going to the area to promote healing. It would be like putting fertilizer on your seed, which are the stem cells.

If you have something more chronic, this tends to be a stem cell-poor environment. In other words, you have osteoarthritis or you've got knee pain that's 5 years old and it's been there for a long time; just putting PRP in it would be like putting fertilizer on dirt without planting a seed first."

The beauty of stem cell therapy is that it mimics a process that is ongoing in your body all the time. Your stem cells are continuously promoting healing, and they do not have to be manipulated in any way. The stem cells naturally know how to home in on areas of inflammation and how to repair damaged tissue.

"All we're doing is harnessing the cells from one location where they're sitting dormant and relocating them to exactly where we want them and we need them to work," Comella says. "Basically, anything inside your body that is inflamed, that is damaged in some way, that is lacking blood supply, the [stem] cells can successfully treat.

That means orthopedics, knee injections, shoulder injections, osteoarthritis, acute injuries, anterior cruciate ligament tears in your back back pain associated with degenerative disc disease or damaged tendons or ligaments, herniated and bulging discs. You can also use it in systemic issues, everything from diabetes, to cardiac, to lungs any tissue organ inside your body that's been damaged.

Autoimmune diseases [can also be treated]. The stem cells are naturally immunosuppressant, meaning they can help quiet down an over reactive immune system and help the immune system function in a more normal way. Neurological diseases, traumatic brain injury, amyotrophic lateral sclerosis, Parkinson's. All of these have to do with tissue that's not functioning properly. The cells can be used to address that."

It's quite impressive, the list of different diseases that could benefit from this intervention. That said, I want to reemphasize that this is not a magic bullet. However, you can dramatically improve the benefits of this intervention by combining it with other healthy lifestyle factors that optimize mitochondrial function, such as eating a healthy whole food diet, exercising, sleeping well, avoiding toxins and detoxifying from toxic influences.

Stem cells can also be used as part of an antiaging program. Comella has used stem cells on herself for several years, and report feeling better now than she did a decade ago.

"The ability to reduce inflammation inside your body is basically making yourself live longer. Inflammation is what kills us all. It's what makes our telomeres shrink. It's what causes us pain and discomfort. It's what makes the tissues start to die. The ability to dose yourself with stem cells and bring down your inflammation, which is most likely caused by any sort of toxin that you've been exposed to breathing air is exposure to toxins this is going to lengthen your lifespan.

I typically will do a dose every six to 12 months, regardless of what's going on. If I have anything that's bothering me, if I tweak my knee at the gym, then I absolutely will come in and do an injection in my knee. I want to keep my tissue healthy for as long as possible.

I want to stay strong. I don't want to wait until something is wrong with me. I think that this is the future of medicine. This is what we're going to start to see. People will begin to get their regular doses of [their own] stem cells and it'll just be common practice."

Keep in mind there's a gradual and progressive decline in the quality and the number of stem cells as you age, so if you're considering this approach, it would be to your advantage to extract and bank your stem cells as early on as possible. U.S. Stem Cell provides a stem cell bank service, so you can store them until a later date when you might need them.

"Your stem cells are never as young as they are right now. Every minute that you live, your telomeres are shrinking. The ability to lock in the youth of your cells today can be very beneficial for you going forward, and for your health going forward. God forbid something happens. What if you have a heart attack? You're not going to get clearance to get a mini-lipo aspirate procedure.

If you have your cells waiting in the bank, ready for you, it becomes very easy to pull a dose and do an IV delivery of cells. It's almost criminal that we're not doing this for every single one of our cardiac patients. This should be standard practice. We should be having every single patient bank their stem cells at a young age and have them waiting, ready and available. The technology is there. We have it. I'm not sure why this technology is not being made available to everyone," she says.

"I think stem cell therapy is very different than traditional medicine. Stem cell therapy may actually make it so that you don't have to be dependent on pharmaceutical medications. You can actually repair the tissue and that's it. This is a very different way of viewing medicine."

If you're interested in having this procedure done, contact the U.S. Stem Cell Clinic on USStemCellClinic.com. You could either have the procedure done at their facility, or if there's a physician in your area providing the service, you can go there. U.S. Stem Cell can help you locate a qualified doctor.

Oftentimes, practitioners will specialize in specific procedures, such as spinal procedures, or knee procedures. There's also a veterinary division, called Vet Biologics, which offers treatment to small pets like cats and dogs, as well as horses.

"One of the things that we've been treating recently is traumatic brain injuries," Comella says. "We had a woman who fell two stories and hit her head. She spent months in a coma and was not able to talk or walk or do any activities. By the time she came to us, it was two years after her injury. The best hospitals in the world told her this was her life 'You're never going to be able to talk or walk or take care of your young children again.' That was just not good enough.

She came to us and we began applying stem cells in a way to allow the cells to cross the blood-brain barrier and to get to her brain. After her first treatment, when she walked into the clinic on her own and began telling me, in full sentences, about the day she had the head injury, tears came down my face. This is the kind of thing that traditional medicine would say is impossible.

We've had patients who were wheelchair-bound, whether it's from multiple sclerosis or Parkinson's, up and out of their chair, literally jogging around cones. This is life-changing Patients who were told they weren't going to return to sports for years are back on the field and playing. There's just many ways that you can heal your tissue to change the course of an injury or a disease."

See more here:
How Stem Cell Therapy Can Help Repair and Regenerate Your Body

Read More...

Stem Cell Cancer Treatment in Russia – Health-Tourism.com

Monday, October 2nd, 2017

This information is intended for general information only and should not be considered as medical advice on the part of Health-Tourism.com. Any decision on medical treatments, after-care or recovery should be done solely upon proper consultation and advice of a qualified physician.

Stem cell cancer treatment

Stem cell cancer treatment is a type of treatment that treats cancer by using stem cell transplant, which is also called peripheral blood stem cell transplant. It is used to try and cure some types of cancer such as myeloma, lymphoma and leukemia. Stem cells are very early blood cells in the bone marrow that develop into red blood cells, white blood cells and platelets. They are needed in order to survive. Your doctor can collect them from a donor or from your blood. After a high dose of treatment which leaves stem cells dead, the stem cells are replaced through an intravenous drip.

Stem cell transplant infuses healthy stem cells into the body to stimulate bone marrow growth, suppress the disease and reduce the possibility of going into remission. Stem cell transplant implies that you can have higher doses of treatment through chemotherapy and radiotherapy. Therefore, the chances of getting cured are higher.

There are two main types of stem cell transplants. You and your doctor will discuss the best choice for you.

This is also known as auto stem cell transplant. Cancer treatment using autologous stem cell transplant uses your own stem cells. It is used mainly to treat myeloma and lymphoma. There is less risk of rejection or graft-versus-host disease, whereby the new donor cells think your cells are foreign and attack them. Ina addition, engraftment is quicker ad side effects are fewer.

How It Works: Your team of doctors collect, freeze and store your own stem cells. You then undergo treatment with chemotherapy or radiation therapy after which your stem cells are thawed and transplanted back into you. You may need to go through the above process twice instead of once. This is known as a tandem or double autologous stem cell transplant.

This type of stem cell transplant is also known as allo stem cell transplant. It involves using stem cells that have been donated. It is mainly used to treat leukemia, aggressive lymphomas and autologous transplants that have failed.

How It Works: Stem cells are donated from a matched donor. You then receive treatment using chemotherapy or radiation therapy after which you receive the donor stem cells.

The type and strength of your high-dose treatment is what will influence any side effects you may have and their severity. Possible side effects include:

After having a stem cell transplant to treat your cancer, you will have regular tests to check your general health. In addition, monitoring the levels of your blood cells, you will have blood tests. Most of the side effects are worse when your blood count is at its lowest. However, as this goes up, the side effects will begin to improve. You will be able to go home when your blood count has reached a safe level.

See the rest here:
Stem Cell Cancer Treatment in Russia - Health-Tourism.com

Read More...

COLUMN: Let’s make biological warfare a crime – Journal Gazette and Times-Courier

Saturday, September 2nd, 2017

Biological and chemical warfare has been used for centuries before WW II, but it was warfare lab at Fort Detrick and Dugway, Utah, authorized by President Roosevelt that delved into the animal disease or anthrax, brucellosis, and Black Plague that are feared and deadly to humans. Whenever anthrax was discovered in herds of sheep or cows, the whole herd would be herded into a dug ditch. Killed, bodies burned and covered with soil, and the land on which the herd grazed would be fenced off and kept free of all animals.

Britain collaborated with America on biological warfare. So when Winston Churchill threatened to bomb four German cities with anthrax bombs if Hitler didnt stop bombing England with V-2 missiles into England, Hitler stopped sending missiles. When the biological warfare labs combined anthrax DNA with a plant disease DNA, a new disease was created that was incurable for when it would be treated it would morph into another disease to fight off the disease was needed like smallpox vaccine.

As my job on the farm was to gather eggs and look after the chickens, I came down with chicken pox and spent a week or more in a darkened room to save my eyesight. But every year I still had to line up, have someone scratch left arm until blood flowed and get small pox vaccine.

Three weeks after 9/11, the secretary of Senate Majority Leader Tom Daschle opened a letter to Tom and the envelope contained a trillion spores of silicon coated anthrax. Tom had opposed President Bushs orders that took away Constitutional rights as did Senator Leahy. His secretary was also poisoned by anthrax spores. It was then blamed on Saddam Hussein but traced to the biological weapons laboratories at Dugway, Utah, and Fort Detrick, Maryland, that President Nixon had ordered closed in 1972 but were kept open.

The labs made synthetic viruses by injecting RNA plant diseases into the DNA of an animal disease to make a new biological warfare disease. They then prepared vaccine to immunize American soldiers going into a nation devastated by this disease. Prisoners in a Maryland prison were offered to have six months off their sentence if they agreed to be vaccinated. They all died but passed this disease on.

While politicians argue over Obamacare, they should push to ban biological warfare the whole world over. Chemotherapy cant distinguish between leukemia or neoplastic cells; transplanted stem cells can replace cells killed by chemotherapy or diseased or dead neural cells such as Alzheimer's, dementia, neural or muscular degeneration.

Paracrine soluble factors produced by stem cells, known as stem cell secretome, mediate the effect of degenerative, inflammatory, and auto-immune is being researched as a medical use itself as cell-free medicinal product. Prochymal was conditionally approved by Canada in 2012 for treatment of children. FDA has approved five hematopoietic stem cell products derived from umbilical cord blood. MSC is derived from bone marrow of adult donors that can make up 10,000 doses that are frozen and stored until needed.

I propose a treaty to halt biological warfare research and have governments work on regenerative stem cell therapies or like therapies that would do away with invasive surgeries, chemotherapy, drugs, to improve the health and lives of people all over the world.

Andrew Patterson was born on a dairy farm two miles south of Sullivan on Feb. 13, 1930. He has attended eight universities for a total of 10 years, lived in 10 countries for 28 years, traveled in 50, speaks and writes Spanish, reads French and German, has written seven encyclopedia articles, and numerous reports and studies for World Bank, Pan American Union, and Economic Development.

Descendant from 15 American Revolutionary ancestors (16th was Cherokee), history is his life's blood, as is telling the truth. He states, "The day I stop learning is the day I am dead, and The hardest thing in life has been to unlearn what has been taught to me as the truth. He has learned there are many men who have stopped WW III from China, Russia, and other countries and it cost them their life. President John F. Kennedy was one of them.

See the original post:
COLUMN: Let's make biological warfare a crime - Journal Gazette and Times-Courier

Read More...

Stem Cell Treatment for Spinal Cord Injury – Beike …

Thursday, August 31st, 2017

Acupuncture

Acupuncture is a technique in which practitioners stimulate specific points on the body - most often by inserting thin needles through the skin. It is one of the most effective practices used in traditional Chinese medicine. Acupuncture stimulates nerve fibers to transmit signals to the spinal cord and brain, activating the bodys central nervous system. The spinal cord and brain then release hormones responsible for making us feel less pain while improving overall health. Acupuncture may also: increase blood circulation and body temperature, affect white blood cell activity (responsible for our immune function), reduce cholesterol and triglyceride levels, and regulate blood sugar levels.

Aquatherapy

Aquatic Physical Therapy is the practice of physical therapy in a specifically designed water pool with a therapist. The unique properties of the aquatic environment enhance interventions for patients with neurological or musculoskeletal conditions. Aquatic therapy includes a wide range of techniques allowing patients to improve their balance, muscle strength and body mechanics. Aquatic therapy works to enhance the rehabilitation process and support effectiveness of stem cell treatment.

Epidural Stimulation

Hyperbaric Oxygen Therapy

Hyperbaric Oxygen Therapy (HBOT) is the medical use of oxygen at a level higher than atmospheric pressure. The equipment required consists of pressure chamber, which may be of rigid or flexible construction, and a means of delivering 100% oxygen into the respiratory system. Published research shows that HBOT increases the lifespan of stem cells after injection and provides an oxygen-rich atmosphere for the body to function at optimum levels.

Nerve Growth Factor (NGF)

Nerve growth factor (NGF) is a member of the neurotrophic factor (neurotrophin, NTFS) family, which can prevent the death of nerve cells and has many features of typical neurotransmitter molecules. NGF plays an important role in the development and growth of nerve cells. NGF is synthesized and secreted by tissues (corneal epithelial, endothelial, and corneal stromal cells), and it can be up-taken by sympathetic or sensory nerve endings and then transported to be stored in neuronal cell bodies where it can promote the growth and differentiation of nerve cells.NGF can exert neurotrophic effects on injured nerves and promote neurogenesis (the process of generating neurons from stem cells) that is closely related to the development and functional maintenance and repair of the central nervous system. It is also capable of promoting the regeneration of injured neurons in the peripheral nervous system, improving the pathology of neurons and protecting the nerves against hypoxia (lack of oxygen)/ischemia (lack of blood supply).

Nutrition Therapy

Occupational Therapy

Occupational therapy interventions focus on adapting the environment, modifying the task and teaching the skill, in order to increase participation in and performance of daily activities, particularly those that are meaningful to the patient with physical, mental, or cognitive disorders. Our Occupational Therapists also focus much of their work on identifying and eliminating environmental barriers to independence and participation in daily activities, similar to everyday life.

Physiotherapy

Physical therapy or physiotherapy (often abbreviated to PT) is a physical medicine and rehabilitation specialty that, by using mechanical force and movements, remediates impairments and promotes mobility, function, and quality of life through examination, diagnosis, prognosis, and physical intervention. We combine our PT with stem cells for maximum physical rehabilitation improvements.

Transcranial Magnetic Stimulation

Research has shown that TMS can effectively treat symptoms of depression, anxiety, neurological pain, stroke, spinal cord injuries, autism and more. This procedure is very simple and noninvasive. During the procedure, a magnetic field generator or coil is placed near the head of the person receiving the treatment. The coil produces small electrical currents in the region of the brain just under the coil via electromagnetic induction. This electrical field causes a change in the transmembrane current of the neuron which leads to depolarization or hyperpolarization of the neuron and the firing of an action potential.

Read more:
Stem Cell Treatment for Spinal Cord Injury - Beike ...

Read More...

Experts caution against stem cell treatments abroad – CNN

Thursday, August 31st, 2017

Story highlights

There's great potential in the field of regenerative medicine, but doctors caution against seeking experimental treatments in an unregulated environment.

Colts head coach Jim Caldwell declined to discuss Manning's health situation when asked about the stem cell treatment at a press conference Monday. Further details of Manning's treatment are not available.

Discussing the choice to go abroad for stem cell treatments puts researchers in an awkward position, because the therapies offered abroad are unregulated and not confirmed to work, but they are based on concepts that the American medical community believes have potential. Generally, however, the consensus is that patients should not try to seek experimental stem cell treatments elsewhere, as there's no telling if they will work or have serious side effects.

"We believe that there is merit to this approach, we just want to see it (carried out) well, ethically and rigorously," said Dr. Joshua Hare, director of the Interdisciplinary Stem Cell Institute at the University of Miami's Miller School of Medicine. Scientists like Hare are trying to gather medical evidence through clinical trials to ensure that these treatments are safe and effective.

Besides orthopedic injuries like Manning's, there are stem cell therapies available elsewhere aimed at heart disease and neurological conditions, even autism. Germany, Panama and Thailand are all popular countries for seeking these kinds of treatments, Hare said.

The basic idea is that stem cells have regenerative potential, and can even form new tissues. Mesenchymal stem cells are a particular kind that can become a variety of cell types, including bone cells and cartilage cells.

And earlier this year, authorities closed down a large stem cell clinic in Germany called the XCell-Center, which had operated through a loophole in the country's regulations regarding unapproved experimental treatments. The clinic had been implicated in the death of an 18-month-old boy after a stem cell treatment; a 10-year-old almost died after receiving something similar.

One problem with going abroad for these unapproved treatments is that there's no follow-up; you won't have anyone back home to take care of any complications that might result, Hare said. In cardiac stem cell trials conducted in this country in people with advanced heart disease, medical professionals do follow up with patients and treat any complications that may arise.

Another concern is that, without proper regulation, any given stem cell therapy abroad may actually be different every time you receive a treatment, said Jeffrey Karp, director of the Laboratory for Advanced Biomaterials and Stem-Cell-Based Therapeutics at Brigham & Women's Hospital in Cambridge, Massachusetts.

There also may not be any regulations on the quality of the treatment, so you really don't know what you're getting, he said.

"Regulatory agencies such as the FDA can ensure that cell therapy that reaches patients is safe, effective, and that quality control is established for isolating the cells, manipulating them outside of the body, and delivering them," Karp said.

A lot of parents believe that stem cell therapies could help their children with autism, although there haven't been any clinical trials in the U.S. to substantiate this, Hare said. In orthopedics and cardiology, on the other hand, there are ongoing investigations; someone like Manning could have potentially joined a clinical trial instead of going abroad, although there's no guarantee that he would have received the treatment rather than a placebo.

The idea of placebo also comes into play here, as with any therapy -- sometimes, just believing strongly that a treatment will heal you actually does change your body, even if that "treatment" isn't actually doing anything.

But there are still significant risks from anything that's unregulated, Karp said.

"While stem cell treatments have been shown to have significant placebo effects during controlled clinical trials, I think patients considering unregulated stem cell treatments need to be aware that they are not optimized and may even do harm," he said.

See the original post:
Experts caution against stem cell treatments abroad - CNN

Read More...

3 Companies Investing In Stem Cell Research – Yahoo Finance

Thursday, August 31st, 2017

Against all odds, stem cell therapies are now getting significant attention from the pharmaceutical industry.

This means that Big Pharma is now seeing that the upside potential of stem cell therapies outweighs the downsides.

While certain things about the stem cell initiative remain controversial - notably embryonic stem cells - some interesting events have occurred recently. These events will, perhaps, encourage more companies to consider investing in stem cell research.

For example, a heart attack victim in London had an experimental surgery that involved the injection of stem cells from his hip into his heart to encourage his heart to repair itself.

The experiment has been successful so far with 37 percent of the victims heart muscle now functioning, up from 21 percent after the heart attack.

Researchers behind this new technique hope that it will increase survival rate from heart attacks by a quarter. Since the Centers for Disease Control and Prevention has said that about 600,000 people die of heart attack in the U.S. every year, this would mean that 150,000 more people could still be alive every year in the U.S.

In light of this development, here are three companies that are investing in stem cell research.

Related:Why Investors Should Closely Watch Celgene

Novartis (NYSE: NVS)

This health care giant has been involved in helping stem cell therapies for about 30 years now, having developed ciclosporin 31 years ago.

Novartis recently broadened its position in the stem cell space by agreeing to take a 15-percent stake in Gamida Cell, an Israeli developer of stem cell therapies. The terms of the agreement has Novartis investing $35 million in Gamida immediately for the stake.

The agreement also gives Novartis the option - which expires in the first half of 2016 - to fully acquire the company, provided certain milestones are achieved regarding the development of NiCord. In this case, the acquisition could come up as early as 2015.

Norvatisannounced on September 6 that it partnered with Regenerex to gain access to Regenerexs stem cell technology, which would help the company develop groundbreaking therapies for underserved diseases.

Johnson & Johnson Company (NYSE: JNJ)

Johnson & Johson kicked off the year by betting $12.5 million on theCapricor Therapeutics(OTC: CAPR) cell therapy program for cardiovascular applications - notably CAP-1002 - through its subsidiary,Janssen Pharmaceuticals, Inc.

Through Janssen Pharmaceuticals, J&J invested in ViaCytes VC-01 combination product being developed for type 1 diabetes. This came after the ViaCyte obtained approval from the FDA to start a clinical trial of the candidate.

J&J is to provide ViaCyte with $20 million.

Celgene Corporation (NASDAQ: CELG)

Celgene is perhaps the boldest big pharmaceutical company out there at the moment, in terms of commitment in stem cell research.

A previousarticleon Benzinga discussed how a robust drug portfolio qualifies the company to be on investors watch list. Its commitment in stem cell adds another reason to watch this company.

Late last year, Celgene entered into an agreement with OncoMed (NASDAQ: OMED) for the development of six anti-cancer stem cell antibodies and certain small molecule stem cell drugs based on OncoMeds study. Celgene committed $155 million in upfront cash to the project.

Under certain conditions in the agreement, the deal could increase to $3.3 billion. The company also entered into an agreement with Human Longevity Inc recently to license, develop and co-promote Celgenes placental cell population, PSC-100. This collaboration also goes to show just how serious Celgene is in holding a significant position in the stem cell space.

See more from Benzinga

2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read this article:
3 Companies Investing In Stem Cell Research - Yahoo Finance

Read More...

New tool for cell-free therapy based on artificial membrane vesicles – Medical Xpress

Tuesday, August 29th, 2017

Scientists at Kazan Federal University's Institute of Fundamental Medicine and Biology, led by Professor Albert Rizvanov, have shown that artificial membrane vesicles generated by Cytochalasin B treatment of human cells retain angiogenic activity.

Vesicles are small packages of material released from cells and act to deliver cargo and messages to adjacent and distant cells. Vesicles are known to be important regulators of normal physiology and have also been implicated in disease, notably cancer. Extracellular vesicles exhibit the biological activity of the cell from which they originate. For example, extracellular vesicles of stem cells are able to promote angiogenesis and regeneration. For this reason, extracellular vesicles represent a promising tool for cell-free therapy to deliver biologically active molecules.

However, the yield of naturally occurring vesicles is too low for practical purposes. Recently, several studies demonstrated the ability to generate a large number of membrane vesicles from cultured cells treated with a drug, Cytochalasin B. This cost-effective approach permits the generation of large quantities of extracellular vesicles. However, it remained unknown whether these Cytochalasin B-induced micro-vesicle (CIMVs) retained characteristic biological properties of their parental cells.

To address this, an international team of investigators, led from Kazan Federal University, Russia by Professor Albert Rizvanov, with international collaborators, characterized the biological activity of membrane vesicles.

The study was published in Oncotarget. The lead author, Dr. Marina Gomzikova, and colleagues described the morphology, molecular composition, fusion capacity and biological activity of Cytochalasin B-induced membrane vesicles (CIMVs). This data suggests that the biophysical, molecular and size distribution properties of CIMVs are similar to natural vesicles. Furthermore, they demonstrated that CIMVs retain the biological properties of the donor cells, as they can stimulate angiogenesis in vitro and in vivo.

CIMVs can now be produced in large quantities and scaled to an industrial production level; potential therapeutic applications to deliver biologically active molecules of CIMVs are now possible.

Explore further: Insulin release is controlled by the amount of Epac2A at the secretory vesicles

More information: Cytochalasin B-induced membrane vesicles convey angiogenic activity of parental cells. Oncotarget. doi.org/10.18632/oncotarget.19723

Read more:
New tool for cell-free therapy based on artificial membrane vesicles - Medical Xpress

Read More...

FDA Cracks Down On Stem-Cell Clinics Selling Unapproved Treatments – NPR

Tuesday, August 29th, 2017

Adult stem cells can be extracted from human fat. Patrick T. Fallon /The Washington Post/Getty Images hide caption

Adult stem cells can be extracted from human fat.

The Food and Drug Administration is cracking down on "unscrupulous" clinics selling unproven and potentially dangerous treatments involving stem cells.

Hundreds of clinics around the country have started selling stem cell therapies that supposedly use stem cells but have not been approved as safe and effective by the FDA, according to the agency.

"There are a small number of unscrupulous actors who have seized on the clinical promise of regenerative medicine, while exploiting the uncertainty, in order to make deceptive, and sometimes corrupt assurances to patients based on unproven and, in some cases, dangerously dubious products," FDA Commissioner Scott Gottlieb said in a statement Monday.

The FDA has taken action against clinics in California and Florida.

The agency sent a warning letter to the US Stem Cell Clinic of Sunrise, Fla., and its chief scientific officer, Kristin Comella, for "marketing stem cell products without FDA approval and significant deviations from current good manufacturing practice requirements."

The clinic is one of many around the country that claim to use stem cells derived from a person's own fat to treat a variety of conditions, including Parkinson's disease, amyotrophic lateral sclerosis (ALS), and lung and heart diseases, the FDA says.

The Florida clinic had been previously linked to several cases of blindness caused by attempts to use fat stem cells to treat macular degeneration.

The FDA also said it has taken "decisive action" to "prevent the use of a potentially dangerous and unproven treatment" offered by StemImmune Inc. of San Diego, Calif., and administered to patients at California Stem Cell Treatment Centers in Rancho Mirage and Beverly Hills, Calif.

As part of that action, the U.S. Marshals Service seized five vials of live vaccinia virus vaccine that is supposed to be reserved for people at high risk for smallpox but was being used as part of a stem-cell treatment for cancer, according to the FDA. "The unproven and potentially dangerous treatment was being injected intravenously and directly into patients' tumors," according to an FDA statement.

Smallpox essentially has been eradicated from the planet, but samples are kept in reserve in the U.S. and Russia, and vaccines are kept on hand as a result.

But Elliot Lander, medical director of the California Stem Cell Treatment Centers, denounced the FDA's actions in an interview with Shots.

"I think it's egregious," Lander says. "I think they made a mistake. I'm really baffled by this."

While his clinics do charge some patients for treatments that use stem cells derived from fat, Lander says, none of the cancer patients were charged and the treatments were administered as part of a carefully designed research study.

"Nobody was charged a single penny," Lander says. "We're just trying to move the field forward."

In a written statement, U.S. Stem Cell also defended its activities.

"The safety and health of our patients are our number one priority and the strict standards that we have in place follow the laws of the Food and Drug Administration," according to the statement.

"We have helped thousands of patients harness their own healing potential," the statement says. "It would be a mistake to limit these therapies from patients who need them when we are adhering to top industry standards."

But stem-cell researchers praised the FDA's actions.

"This is spectacular," says George Daley, dean of the Harvard Medical School and a leading stem-cell researcher. "This is the right thing to do."

Daley praised the FDA's promise to provide clear guidance soon for vetting legitimate stem-cell therapies while cracking down on "snake-oil salesmen" marketing unproven treatments.

Stem-cell research is "a major revolution in medicine. It's bound to ultimately deliver cures," Daley says. "But it's so early in the field," he adds. "Unfortunately, there are unscrupulous practitioners and clinics that are marketing therapies to patients, often at great expense, that haven't been proven to work and may be unsafe."

Others agreed.

"I see this is a major, positive step by the FDA," says Paul Knoepfler, a professor of cell biology at the University of of California, Davis, who has documented the proliferation of stem-cell clinics.

"I'm hoping that this signals a historic shift by the FDA to tackle the big problem of stem-cell clinics selling unapproved and sometimes dangerous stem cell "treatments" that may not be real treatments," Knoepfler says.

Read the original here:
FDA Cracks Down On Stem-Cell Clinics Selling Unapproved Treatments - NPR

Read More...

Cellect Biotechnology Ltd Provides Corporate Update and Reports Second Quarter 2017 Financial Results – Markets Insider

Tuesday, August 22nd, 2017

TEL AVIV, Israel, Aug. 21, 2017 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP, TASE: APOP), a developer of innovative technology which enables the functional selection of stem cells, today provided a corporate update and announced financial results for the second quarter ended June 30, 2017.

"We are very pleased with our accomplishments in the first half of 2017," said Dr. Shai Yarkoni, Chief Executive Officer. "As planned, 2017 is turning into a transformative year for Cellect Biotechnology. Cellect initiated its Phase I/II study on cancer patients undergoing matched related allogeneic HSCT transplantation and reported positive results in the first patient followed by the approval to recruit two more patients. Further, Cellect held a pre-IND meeting with the FDA that was very positive and Cellect is moving ahead with its plan to submit an IND".

Important progress was achieved with the company's IP portfolio the major patent covering the composition of matter and use of the ApotainerTm was issued in US and Russia, the collaboration with Entegris was further consolidated by receiving a BIRDF non-equity grant, and the development of the Apotainer was accelerated.

In addition, world renowned leaders joined the Company (i.e KOLs from Harvard Medical school, executives from Pfizer and Merck) and the Company teamed up with Boston based Locust-Walk business development group for planning and launching a business development campaign before the end of the year.

During the second quarter, the Company made the following announcements -

Recent Corporate Highlights:

Second Quarter 2017 Financial Results:

Balance Sheet Highlights:

* For the convenience of the reader, the amounts above have been translated from NIS into U.S. dollars, at the representative rate of exchange on June 30, 2017 (U.S. $1 = NIS 3.496).

The Company's consolidated financial results for the three and six months ended June 30, 2017 are presented in accordance with International Financial Reporting Standards.

About Cellect Biotechnology Ltd.

The Company is developing an innovative technology which enables the functional selection of stem cells based on their sensitivity to apoptosis. This functional-based selection is a breakthrough technology in the ability to isolate stem cells from any given tissue, and may improve a variety of stem cells applications.

The Company's first planned product line is expected to include unique containers for cell selection in an apoptosis-inducing microenvironment. Cellect's first planned commercial product candidate is a medical kit designed for the cancer treatment bone marrow transplantations market, as well as other markets which require cell selection. The Company plans that in the future its technology will be integrated in many production procedures of stem cell-based products.

The Company's securities are currently traded on both the NASDAQ Capital Market and the Tel Aviv Stock Exchange (NASDAQ: "APOP", "APOPW", TASE: "APOP").

Forward Looking Statements

This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss our anticipated performance in 2017, the expected characteristics of our first product line, our beliefs about the future integration of our technology into the production procedures of stem cell-based products and the potential of our technology and its proposed uses. These forward-looking statements and their implications are based on the current expectations of the management of the Company only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2016 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, http://www.sec.gov and in the Company's periodic filings with the SEC and the Tel-Aviv Stock Exchange.

Cellect Biotechnology Ltd

Consolidated Statement of Operation

Convenience

translation

Six months

ended

Six months ended

Three months ended

June 30,

June 30,

June 30,

2017

2017

2016

2017

2016

Unaudited

Unaudited

U.S. dollars

NIS

(In thousands, except share and per

share data)

Research and development expenses

1,495

5,227

3,679

2,405

1,848

General and administrative expenses

1,729

6,046

3,547

3,497

1,617

Other income

-

-

(280)

-

(280)

Operating loss

3,224

11,273

6,946

5,902

3,185

Financial expenses (income) due to warrants exercisable into shares

1,519

5,312

-

(1,461)

-

Other financial expenses (income), net

135

468

23

161

(5)

Total comprehensive loss

4,878

17,053

6,969

4,602

3,180

Loss per share:

Basic and diluted loss per share

0.045

0.158

0.088

0.042

0.039

Weighted average number of shares outstanding used to compute basic and diluted loss per share

108,034,218

108,034,218

79,113,097

108,462,728

81,456,571

Cellect Biotechnology Ltd

Consolidated Balance Sheet Data

ASSETS

See the original post:
Cellect Biotechnology Ltd Provides Corporate Update and Reports Second Quarter 2017 Financial Results - Markets Insider

Read More...

Scientists 3D-print ‘high-resolution’ living tissue RT UK – RT.com – RT

Saturday, August 19th, 2017

Published time: 18 Aug, 2017 16:05

Oxford University scientists have found a ground-breaking way of 3D-printing living tissue that could pave the way for regenerative medicine.

The new way to 3D-print stem cells to recreate complex living tissues was devised by Oxford scientists in collaboration with Bristols School of Cellular and Molecular Medicine.

Read more

The discovery could revolutionize regenerative medicine as it allows for the reproduction of complex tissue that could replace or repair damaged or severed areas of the body.

The versatility and robust nature of our approach provides a new set of tools for bottom-up tissue engineering at a low cost, researchers claim in their paper, published in Scientific Reports.

One of the main hurdles of 3D-printing organic matter has been that cells move within the printed structures, and the soft scaffoldings supporting them tend to collapse on themselves.

The new method could see the production of tissue in self-contained cells that support the structures and could help them keep their shape.

We were aiming to fabricate 3D living tissues that could display the basic behaviors and physiology found in natural organisms, said Alexander Graham, lead author and 3D Bioprinting Scientist at OxSyBio (Oxford Synthetic Biology).

The research team wanted to produce prints with the same cell complexity of native tissue.

Read more

To date, there are limited examples of printed tissues, which have the complex cellular architecture of native tissues.

Hence, we focused on designing a high-resolution cell printing platform, from relatively inexpensive components, that could be used to reproducibly produce artificial tissues with appropriate complexity from a range of cells including stem cells.

The new method seems to improve the survival rate of cells, as they had a high viability average of 90 percent.

The bioprinting approach developed with Oxford University is very exciting, as the cellular constructs can be printed efficiently at extremely high resolution with very little waste, said Adam Perriman, of the University of Bristols School of Cellular and Molecular Medicine.

The researchers believe the approach could put a halt to animal testing and play a key role in drug and toxin screening.

There are many potential applications for bioprinting and we believe it will be possible to create personalized treatments by using cells sourced from patients to mimic or enhance natural tissue function, said Sam Olof, chief technology officer at OxSyBio.

View original post here:
Scientists 3D-print 'high-resolution' living tissue RT UK - RT.com - RT

Read More...

News: Eddie Izzard To Appear At Intimate Fringe Benefit – Beyond The Joke

Saturday, August 19th, 2017

Eddie Izzard is to appear in a 50-seater venue at the Edinburgh Fringe on Saturday August 19.

Izzard is taking part in a run of gigs featuring comedy promoter Stephen Garland, who runs comedy gigs in Spain. Garland is telling his story onstage of being diagnosed with PPMS and raising money to get to Russia to stop his disease with Stem Cell Therapy. More info atwww.stopmyppms.com

The show title -'The Pre-Disposed'- came about as a correction by a Psychologist that it is politically incorrect to refer to PPMS, despite its 'No Treatment, No Cure' reality as a 'Terminal Disease'.Which I had done and was informed that I should use the more PC term, a Pre-Disposed illness, explains Garland.

Each evening Garland will bejoined by a different comedian. Many of them are featured in Garland's story. The idea is to bring promoter and comedians together to discuss in terms of comedy whether 'the comic' is somehow pre-disposed to perform and can it be what defines the comedy style that the public love so much.

This list of comics represents for me some of the coalface of Fringe innovation and I am truly honoured that they will join my humble amateurish performance, says Stephen.

Fans will need to go to tonight's gig (August 18) to find out how to get tickets for Izzard's appearance.

WHERE: Venue 156 Banshee Labyrinth ~ Banqueting Hall

WHEN: August 12 - 19 inclusive

TIME: 21:50

TICKETS: FREE - followed by a bucket with all proceeds going towww.stopmyppms.com

Aug 15 | TueCarey Marx- (ENG) - Fringe Show - The Afterwife -https://tickets.edfringe.com/whats-on/carey-marx-the-afterwife

Another fringe favourite and loved in festivals across the planet, constant innovator who each year brings something extraordinary to Edinburgh.

Aug 16 | Wed -Simon Munnery- (ENG) - Fringe Show - Simon Munnery: Renegade Plumber -https://tickets.edfringe.com/whats-on/simon-munnery-renegade-plumber

A legend of alternative comedy and coming to the Fringe weaving his surreal comedy brilliance in Edinburgh since before anyone can remember.

Aug 17 | Thu -Alexis Dubus- (ENG) - Fringe Show - Marcel Luconts Whine List -https://tickets.edfringe.com/whats-on/marcel-lucont-s-whine-list

One of the finest comedians whether as himself or his internationally award winning comedy creation Marcel Lucont. Alexis is a festival favourite loved from New Zealand to Barcelona.

Aug 18 | Fri -Trevor Lock- (ENG) - Fringe Show - Trevor locks Community Circle -https://tickets.edfringe.com/whats-on/trevor-lock-s-community-circle

Trevor has a totally unique style built on sheer charm that makes his largely 'joke free' Community Circle an unmissable comedy event that has wooed fans across the world. Trevor was instrumental in bringing a professional gravitas to a very fledgling comedy scene in Rio through 2016. Already packing a 5 star review from Scotsman!!!

Aug 19 | Sat -EDDIE IZZARD.

See the original post here:
News: Eddie Izzard To Appear At Intimate Fringe Benefit - Beyond The Joke

Read More...

Northern Ireland mum fighting MS: Russian medics are now my last hope – Belfast Telegraph

Thursday, August 17th, 2017

Northern Ireland mum fighting MS: Russian medics are now my last hope

BelfastTelegraph.co.uk

A young Co Down mum is bravely undergoing a gruelling stem cell transplant in Russia in what she believes is her last hope of enjoying some quality of life.

http://www.belfasttelegraph.co.uk/news/northern-ireland/northern-ireland-mum-fighting-ms-russian-medics-are-now-my-last-hope-36023340.html

http://www.belfasttelegraph.co.uk/life/features/article36023337.ece/4289a/AUTOCROP/h342/2017-08-12_lif_33652492_I8.JPG

A young Co Down mum is bravely undergoing a gruelling stem cell transplant in Russia in what she believes is her last hope of enjoying some quality of life.

Lindsay Rice (35) from Warrenpoint has exhausted every treatment on the health service - including chemotherapy normally given to cancer patients - in the hope of treating the chronic condition Rapidly Evolving Severe Relapsing Remitting Multiple Sclerosis.

Paralysis and temporary sight loss are just a few of the many debilitating symptoms which have left the mum-of-two unable to enjoy normal family life.

Desperate to get her help, her family launched an appeal on Facebook and Go Fund Me to raise 50,000 to send her to the National Pirogov Medical Surgical Centre in Moscow where she arrived two weeks ago to start her stem cell transplant.

The treatment alone is expected to cost up to 45,000 and, incredibly, in just 12 weeks the family has raised 32,000 towards a 50,000 target thanks to generous support from friends and the public.

Lindsay, who is married to Liam (36), a financial advisor, has two children, Jamie (17) and Olivia (8).

Liam says: "This is her last hope and she is doing it for her family and her kids and that's what she is focusing on. She just wants to be able to live a normal life and do normal things with the family."

Since starting her treatment on August 1 she has been keeping a daily dairy of her progress through a Facebook page - Lindsay's Last Hope.

While the groundbreaking treatment known as HSCT (Haematopoietic Stem Cell Transplant) is not a cure for MS, Lindsay's hope is that it will halt the progression of the disease and stop the frequent and severe relapses which are destroying her health.

Lindsay will spend a month in the clinic, most of it in isolation, and when she comes home she faces a long recovery period when she will have to remain isolated for up to a year due to the risk of infection.

HSCT aims to 'reset' the immune system to stop it attacking the central nervous system. It uses chemotherapy to remove the harmful immune cells and then rebuild the immune system using a type of stem cell found in the patient's bone marrow.

The haematopoietic stem cells used in the treatment can produce all the different cells in the blood, including immune cells. However, they can't regenerate permanently damaged nerves or other parts of the brain and spinal cord.

Lindsay has successfully had over two million stem cells extracted in a tough procedure which involved having a catheter inserted into her jugular vein. She has also had her head shaved this week in preparation for starting chemotherapy today.

The chemotherapy will wipe out her immune system and she will then have her stem cells transplanted back into her blood by a drip to help regrow a new, stronger immune system.

She will then have to spend 10 days in complete isolation while her new immune system builds.

Also, since arriving in Russia she has been told that her MS is now much worse than she realised and is now at the Secondary Progressive stage.

People with Secondary Progressive MS don't tend to recover completely from a relapse and can expect a general worsening of symptoms, making the treatment even more time-critical.

In a further blow, tests have picked up a potentially dangerous three-centimetre active lesion on her spine which wasn't spotted during MRI's here.

Lindsay faces a tough few weeks in her bid to halt the progression of the disease but as her husband Liam explains, the alternative is the prospect of life in a wheelchair: "Lindsay has come through a lot since her teens.

"She had Jamie quite young at 18 and her condition seemed to really deteriorate after that. She went to a lot of consultants and had many tests but it wasn't until after she had Olivia that she was finally diagnosed in 2011.

"She never knows from day to day how it will affect her. Fatigue is the number one problem and that is crippling. I would come home from work and after dinner she has to go to bed, and even sleep doesn't help it.

"It stops her from doing simple things like taking our daughter to the park or taking the dog for a walk.

"Her motability is not as good as an average person and the other big issue is the relapses.

"They have become very frequent and each relapse is worse in terms of how severe it is. During her last one in February she had to go into hospital and also had to use a walking frame.

"A common misconception is that after each relapse you go back to normal but that's not the case. It leaves its mark and any damage done is permanent. The nature of the relapses could leave her in a wheelchair."

It was after her last relapse and having exhausted all options for treatment on the Health Service that Lindsay decided she wanted to try HSCT.

Her neurologist in Belfast supported her decision and the family applied to the Russian clinic just 12 weeks ago expecting to wait up to two years before admission.

They were surprised to be offered a cancellation on August 1 leaving them facing a race against time to raise 50,000 to cover the cost of treatment and expenses.

Liam says: "We thought we would have at least 12 months and up to two years to get the money together and it has been amazing to see how people have rallied round and what they have done just from the kindness of their hearts, especially strangers.

"We've had quizzes and coffee mornings and online auctions and I recently did the Four Peaks challenge with a group of friends. Lindsay's mum and her best friend are organising a lot of events and we still have some way to go but we are amazed at how much has been raised and donated in such a short time."

Liam flew to Russia with Lindsay on July 31 and stayed with her for five days while she underwent tests to determine that she was suitable for the treatment.

It has already been a punishing two weeks for Lindsay who has come through a batch of invasive procedures including having a catheter inserted in her jugular to extract the stem cells.

Liam says: "It is an intense treatment and Lindsay is so positive and coping brilliantly. She got her hair cut short before she went and decided to have it shaved this week before the chemo starts and it falls out.

"She will have to spend 10 days in complete isolation to allow her immune system to build again and that will be tough.

"She will hopefully be home after 30 days and then when she comes home she will have a long recovery and will have to isolate herself from society for up to a year to keep her safe from infection.

"We will have to deep clean the house and we will all have to wear face masks as she can't risk even getting a cold."

Liam is back at work and trying to keep things as normal as possible at home for the couple's two children, who he said are coping well: "Jamie is 17 and approaching adulthood and understands why she is doing it and is okay, but obviously his mum is away and he has his sixth year exam results coming and he misses her.

"Olivia seems to be fine too. She understands her mum has MS, which stops her doing things with her and she knows this treatment is to help her to be a better mother.

"I've been trying as much as possible to keep her occupied with play dates and sleepovers."

The couple have been impressed by the level of care in the clinic and Lindsay has had the chance to meet and get to know other MS patients from all over the world.

Liam has nothing but admiration for her strength and the positive way she is enduring the extreme procedures she faces.

He adds: "Lindsay is the most determined person you could ever possibly meet. She has had bad days and it can be demoralising for her but she is determined to be as positive as she can be.

"It is not a cure. MS doesn't have a cure but we hope it will stop the progress of the disease. We just hope it will halt it by rebooting her immune system and hopefully stop the severe relapses."

Liam adds: "It is desperately hard and stressful for all of us and we have to put a positive spin, in the grand scheme of things it is just for a month of her life."

Follow Lindsay's journey at Facebook/Lindsay's Last Hope - HSCT in Russia

Fundraising continues as the family has only until the end of the month to reach their target. You can support this young mum in her bid to enjoy a normal quality of life by going to https://www.gofundme.com/lindsay-slasthope

Belfast Telegraph

View original post here:
Northern Ireland mum fighting MS: Russian medics are now my last hope - Belfast Telegraph

Read More...

Former basketball star Greg Friel in fight of his life – Sports – fosters … – Foster’s Daily Democrat

Thursday, August 17th, 2017

Mike Whaley mwhaley@fosters.com @mwhaley25

Greg Friel can deal with the pain, as bad as it can be. Its the uncertainty about his future well-being that makes life difficult.

A former basketball star at Oyster River High School and Dartmouth College, Greg, 38, was diagnosed with relapsing remitting multiple sclerosis in 2010.

This unpredictable, often disabling disease of the central nervous system has weakened his body, particularly his legs below the knees, to the point where he often has to get around with a cane, and sometimes a walker.

Im in constant pain, he said. Its terrible. But Ive got a beautiful wife. Ive got a business where Im my own boss. Its a challenge. If you know the Friels, were up for a challenge. But its scary.

Fortunately, for Greg, there might be a light at the end of the tunnel. Next month, he will fly to Russia with his Uncle Bob for hematopoietic stem cell transplantation (HSCT). After being on the waiting list for three-plus years, Greg was recently granted admission to the treatment program.

The catch is that the cost for travel and treatment will be around $100,000. The treatment is not covered by insurance, so Gregs wife, Anastagia, has set up a GoFundMe page to raise funds to pay for the trip and treatment (https://www.gofundme.com/gregfrielhsct). As of Saturday morning, nearly $53,000 has been raised in three weeks.

Greg flies to Moscow on Sept. 24 for the month-long treatment, which begins on Sept. 26 at Piragov Hospital.

MS is so unpredictable, Anastagia said. Its hard to see my husband, a pillar of strength in the family, going through a weak time.

Hes such a positive person, she added. Hes charismatic. Theres such a light around him. Its hard to deny his charisma, and hes charming.

The treatment includes chemotherapy, where Greg said they shock your system down to zero. Good stem cells are injected, so basically its a stem cell rebirth.

It wasnt easy for Greg to reach out for help. An independent financial advisor in Boston, he was used to being the one helping out. It was in his nature to give.

My wife, my mom and my siblings told me I needed to open myself up, said Greg, who stands 6-foot-5. It was difficult. But if you get it early, you get proactive and you get things done, you can be in fine shape.

Thats the high-road approach Greg is taking.

Thats the athletic mentality, he said. Youre competitive because you care.

nnn

Greg comes from primo competitive stock. His dad, the late Gerry Friel, was the head mens basketball coach at the University of New Hampshire for 20 seasons (1969-89).

Greg is the middle child of five siblings. All of them played basketball at Oyster River and all five scored over 1,000 career points (Keith tallied over 2,000 points). They also all played Division I college basketball: Jennifer (UNH), Keith (Notre Dame, Virginia), Greg (Dartmouth), Jeremy (UNH) and Jilliane (UNH).

Greg and Keith starred at Oyster River in the mid-1990s, leading the Bobcats to back-to-back Class I championships in 1995 and 96.

Keith speaks fondly of those years playing with his brother. Greg was always two steps ahead and always competing. He did the little things, all the extra stuff that others didnt want to do. He loved to win, even if that meant diving for a ball or taking charges.

Greg was Wojo before Wojo, Keith said, referencing the feisty former Duke University guard of the late 1990s, Steve Wojciechowski. He was always firing up the other team, getting in their heads.

Plus he had that deadly 3-point stroke.

Greg graduated in 1997, attended New Hampton School for a post-graduate year where he counted future NBA star Darius Songaila (whos still a close friend) and Pistol Pete Maravichs son, Jason, among his teammates. Greg started for New Hampton and led them to the New England Class A prep championship game where they lost to Maine Central Institute.

Originally committed to the University of North Carolina at Wilmington, Greg decided to accept an offer from Dartmouth, coached by Somersworth native Dave Faucher, a former assistant at UNH under Gregs dad.

Two of Fauchers sons played at Lebanon High School, whom Oyster River beat in the 1995 Class I championship, 55-52. Greg set a tournament championship record with five 3-pointers in that game, a record he still shares 22 years later with two other players.

UNC-Wilmington would not let him out of his commitment, so he had to sit out a year before joining the Dartmouth team in the fall of 1999.

Greg played four years for the Big Green, serving as a captain as a senior. He graduated with a degree in economics and a minor in sociology.

As a player he got the chance to compete against both his brothers, although Jeremy laughs, I was on the bench while he was playing. I didnt get in.

Greg has been a financial advisor for 14 years, the last nine as his own man, running his own business.

He met his future wife while judging a beauty pageant in Las Vegas in 2009. A successful model, Anastagia has been Miss Teen Florida USA, Miss Florida USA and Miss Bahama Universe. She has also appeared in Sports Illustrateds swimsuit issue.

She actually didnt want to be at that particular pageant in 2009, but went at her moms behest and finished second.

They communicated on Facebook and it blossomed from there. Greg and Anastagia were married in May of 2014.

nnn

In 2010, when Greg was diagnosed with MS, it started with headaches.

I was feeling weak, he said. I was working 80-90 hours a week, so I was thinking it could have been that. I just kept getting weaker and weaker, my legs mostly. I was feeling lethargic. I didnt have any energy.

His legs hurt. He described it as a charley horse: You cant move, he said. Youre stuck in mud. It felt like youre cutting (to the basket) and someone knees your leg muscle. Thats what it felt like all the time.

At its worse, Greg said he couldnt move, couldnt walk, couldnt get out of bed.

Greg took a very aggressive drug called Tysabri for 4 years that cost $22,000 a month for an infusion and was partially covered by insurance. But it wasnt a cure and he didnt know the long-term effects. That was a concern since he and Anastagia want to have children.

Now theres hope with the Russian treatment.

Gregs cousin, Brendan Friel, who suffered from the same MS, went to Russia for treatment and is back in good health.

He just had his three-year stem cell anniversary, Greg said. And now hes working full-time.

Anastagia said they did their research. (The treatment) is invasive, but its got a good track record, she said.

What Greg finds irritating is that the procedure is covered by insurance for cancer, ALS and rheumatoid arthritis, but not MS.

Its crazy, he said.

As expected, its been difficult for his family.

Its heart-wrenching, said Joan, his mom. Its been more debilitating in the past year than ever. Hes going downhill since Thanksgiving of last year. Its one little setback after another this time. He has to do something; otherwise it will get so much worse.

Joan said shes there as a mom. Thats my job and I embrace it for all my children. Im a sounding board.

She added, I dont need to be intrusive. Im there if they need me and want me and, sometimes, if they dont.

Greg maintains an upbeat attitude.

Im good, he said. I try to stay positive. Ive always been a pretty positive person mentally.

nnn

The Friels have been touched by the outpouring of donations in such a short time, some from old adversaries or teammates Greg hasnt seen in 20 years.

Its not like one person wrote a check for $20,000, Greg said. Over 300 people have donated. Its very humbling. Its nice to see the support.

Later this month there will be a fundraiser at The Warehouse Bar & Grille, 40 Broad Street, in Boston to raise funds for Gregs treatment. It is being put together by a couple of old basketball opponents, Cliff Dever (Timberlane) and Marshall Chrane (Bishop Brady).

Chrane was on the Brady team that Gregs OR team beat in the 1996 Class I final, 58-49. Chrane returned the favor in 1997, hitting two foul shots with no time on the clock to beat Oyster River by a point in the tournament quarterfinals, Gregs last high school game.

The fundraiser will take place from 1 to 4 p.m. on Aug. 27.

There will be raffles, which include, among others, items donated by former pro and college football coach, Chip Kelly; UNH hockey coach Dick Umile and UMass-Amherst athletic director Ryan Bamford, Gregs old AAU teammate.

The journey to get Greg his treatment is certainly gaining momentum.

Were determined to get this right, he said.

Anastagia agrees.

I dont want anyone to be fighting alone, she said. Were committed to fighting this thing together.

Which is what good teammates do.

More:
Former basketball star Greg Friel in fight of his life - Sports - fosters ... - Foster's Daily Democrat

Read More...

Europe Mesenchymal Stem Cells Market Forecast 2022 Study covering Strategies, Application, Growth Estimation and … – satPRnews (press release)

Thursday, August 17th, 2017

A new research document with title Europe Mesenchymal Stem Cells Market by Manufacturers, Countries, Type and Application, Forecast to 2022 covering detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes regions like Germany, UK, France, Russia, Italy and important players/vendors such as Thermo Fisher, Bio-Techne, ATCC, etc The report will help user gain market insights, future trends and growth prospects for forecast period of 2017-2022

Request a sample report @ https://www.htfmarketreport.com/sample-report/643003-europe-mesenchymal-stem-cells-marketMesenchymal Stem Cells (MSC), also termed Mesenchymal Stromal Cells, are multipotent cells that can differentiate into a variety of cell types and have the capacity for self-renewal.

Scope of the Report:

This report focuses on the Mesenchymal Stem Cells in Europe market, especially in Germany, UK, France, Russia, and Italy. This report categorizes the market based on manufacturers, countries, type and application.

Market Segment by Manufacturers, this report covers

Lonza

Thermo Fisher

Bio-Techne

ATCC

MilliporeSigma

PromoCell GmbH

Genlantis

Celprogen

Cell Applications

Cyagen Biosciences

Axol Bioscience

Market Segment by Countries, covering

Germany

UK

France

Russia

Italy

Market Segment by Type, covers

Human MSC

Mouse MSC

Rat MSC

Other

Market Segment by Applications, can be divided into

Research Institute

Hospital

Others

Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/643003-europe-mesenchymal-stem-cells-market

There are 17 Chapters to deeply display the Europe Mesenchymal Stem Cells market.

Chapter 1, to describe Mesenchymal Stem Cells Introduction, product type and application, market overview, market analysis by countries, market opportunities, market risk, market driving force;

Chapter 2, to analyze the manufacturers of Mesenchymal Stem Cells, with profile, main business, news, sales, price, revenue and market share in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers in Europe, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the Europe market by countries, covering Germany, UK, France, Italy and Russia, with sales, price, revenue and market share of Mesenchymal Stem Cells, for each country, from 2012 to 2017;

Chapter 5 and 6, to show the market by type and application, with sales, price, revenue, market share and growth rate by type and application, from 2012 to 2017;

Chapter 7, 8, 9, 10 and 11, to analyze the key countries by manufacturers, Type and Application, covering Germany, UK, France, Italy and Russia, with sales, revenue and market share by manufacturers, types and applications;

Chapter 12, Mesenchymal Stem Cells market forecast, by countries, type and application, with sales, price, revenue and growth rate forecast, from 2017 to 2022;

Chapter 13, to analyze the manufacturing cost, key raw materials and manufacturing process etc.

Chapter 14, to analyze the industrial chain, sourcing strategy and downstream end users (buyers);

Chapter 15, to describe Mesenchymal Stem Cells sales channel, distributors, traders, dealers etc.

Chapter 16 and 17, to describe Mesenchymal Stem Cells Research Findings and Conclusion, Appendix, methodology and data source

.Continued

View Detailed Table of Content @ https://www.htfmarketreport.com/reports/643003-europe-mesenchymal-stem-cells-market

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=643003Contact Us:CRAIG FRANCIS (PR & Marketing Manager)sales@htfmarketreport.comPh: +1 (206) 317 1218

Go here to see the original:
Europe Mesenchymal Stem Cells Market Forecast 2022 Study covering Strategies, Application, Growth Estimation and ... - satPRnews (press release)

Read More...

Page 17«..10..16171819..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick